Lesson plan
AB0124
AB0124 is a serotonin 5-HT 2A receptor positive allosteric modulator. It is highly selective for potentiation of the serotonin 5-HT 2A receptor, with no potentiation of the serotonin 5-HT 2B and 5-HT 2C receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT 2 receptors. AB0124 has been studied in combination with the serotonin 5-HT 2 receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.
Article summary
AB0124 is a serotonin 5-HT 2A receptor positive allosteric modulator. It is highly selective for potentiation of the serotonin 5-HT 2A receptor, with no potentiation of the serotonin 5-HT 2B and 5-HT 2C receptors. In addition, it showed no orthosteric agonistic activity at any of the serotonin 5-HT 2 receptors. AB0124 has been studied in combination with the serotonin 5-HT 2 receptor agonist (R)-DOI in animal models of cocaine use disorder. The chemical synthesis of AB0124 has been described. The drug was patented in 2022 and was first described in the scientific literature by 2024.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.